Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune activation in ... and augment the anti-tumor responses achieved with PD-1/PD-L1 ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

In NSCLC cohort, the combination of ifebemtinib and garsorasib, as a dual-oral, chemotherapy-free regimen, demonstrated compelling clinical benefit including high response rates and durable efficacy, ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- ...

Bcl6 regulates the lineage stability and suppressive function of Treg cells in head and neck squamous cell carcinoma ...

BioLineRx shares were higher after the company reported favorable data from a pilot phase of a drug study of pancreatic cancer patients. Shares rose 45% to $5.51 Friday and are down about 36% this ...

Phanes Therapeutics begins patient dosing in clinical study of mavrostobart in combination with chemotherapy: San Diego Wednesday, May 28, 2025, 18:00 Hrs [IST] Phanes Therapeutic ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...